Mutations of the GATA1 gene on chromosome X have been found in almost all cases of transient myeloproliferative disorder and acute megakaryoblastic leukemia (AMKL) accompanying Down syndrome (DS). Although most GATA1 mutations lead to the expression of GATA1s lacking the N-terminal activation domain, we recently found two novel GATA1 proteins with defects in another N-terminal region. It has been suggested that loss of the N-terminal portion of GATA1 might interfere with physiological interactions with the critical megakaryocytic transcription factor RUNX1, and this would imply that GATA1s is not able to interact properly with RUNX1. However, the interaction domain of GATA1 remains controversial. In this study, we show that GATA1 binds to RUNX1 through its zinc-finger domains, and that the C-finger is indispensable for synergy with RUNX1. All of the patient-specific GATA1 mutants interacted efficiently with RUNX1 and retained their ability to act synergistically with RUNX1 on the megakaryocytic GP1ba promoter, whereas the levels of transcriptional activities were diverse among the mutants. Thus, our data indicate that physical interaction and synergy between GATA1 and RUNX1 are retained in DS-AMKL, although it is still possible that increased RUNX1 activity plays a role in the development of leukemia in DS.
Introduction
Down syndrome (DS), which is caused by trisomy 21, is one of the most common human chromosomal abnormalities. Children with DS have an approximately 20-fold higher incidence of leukemia than the general population. 1 The majority of leukemia cases associated with DS are acute megakaryoblastic leukemia (AMKL). Recently, we and others [1] [2] [3] [4] [5] [6] [7] demonstrated that acquired mutations of the GATA1 gene were detected in almost all cases of DS-related AMKL (DS-AMKL) and transient myeloproliferative disorder (TMD), 'a preleukemia' that may be present in as many as 10% of newborn infants with DS. In each case, the mutation resulted in the introduction of a premature stop codon in the gene sequence encoding the N-terminal activation domain and expression of an alternative 40-kDa translation product (GATA1s) from a downstream initiation site.
Mutagenesis of the GATA1 gene is a very early event in the development of DS-AMKL, occurring during the process of multi-step leukemogenesis. However, mutations in GATA1 may not be the first event, because the GATA1 gene is located on the X chromosome. Although interaction of GATA1 with one or more genes in chromosome 21 presumably contributes to the development of DS-AMKL, the genes on chromosome 21 that promote the megakaryoblastic leukemia associated with DS are currently unknown. 8 The RUNX1 gene is localized to chromosome 21, within the critical region for DS. RUNX1 is a hematopoietic transcription factor that is frequently mutated and translocated in leukemia. 9 RUNX1 is essential for the terminal differentiation of megakaryocytic progenitors. Haploinsufficiency of RUNX1 causes thrombocytopenia, 10, 11 whereas overexpression facilitates megakaryocytic differentiation. 12 Interestingly, a recent study showed that overexpression of the Runx1 gene in BXH2 mice, which have a replication-competent retrovirus, results in an increased frequency of megakaryoblastic leukemia, suggesting that increased RUNX1 dosage is leukemogenic in the myeloid lineage. 13 Recent reports have shown that GATA1 physically interacts with RUNX1. Elagib et al. 12 showed that both the N-terminal (residues 1-85) and the C-terminal (residues 319-413) regions of mouse GATA1 are critical for binding RUNX1. These results suggested that GATA1s in DS-AMKL patients is not able to interact with RUNX1 and therefore forms an aberrant megakaryocytic transcriptional complex lacking RUNX1. Furthermore, an increased amount of free RUNX1 is available in these cases owing to the presence of trisomy 21 and decreased binding by GATA1s. This combination of decreased functionality of GATA1s and increased levels of RUNX1 might have an important role in the predisposition of DS patients to develop AMKL.
14 However, the location of the interaction domain within GATA1 is controversial. Waltzer et al. 15 reported that GATA1 interacts with RUNX1 through its zinc-finger domain, and that the N-terminal domain of GATA1 is dispensable for the interaction with RUNX1.
To better understand the mechanisms of normal megakaryopoiesis and leukemogenesis in DS, we attempted to determine the interaction domain of GATA1 for binding RUNX1. We showed that GATA1 bound to RUNX1 through its zinc-finger domain. All of the patient-specific GATA1 mutants interacted efficiently with RUNX1 through their zinc-finger domains and retained synergy with RUNX1 on the megakaryocytic GP1ba promoter, whereas the levels of transcriptional activities were diverse among the mutants. Thus, our data indicate that physical interaction and synergy between GATA1 and RUNX1 are retained in DS-AMKL, although it is still possible that increased dose of RUNX1 activity plays a role in the development of leukemia in DS.
Materials and methods

Construction of plasmid vectors
LNCX-F-AML1b was described previously. 16 Human GATA1 cDNA from GATA1 pET#1 (kindly provided by Dr Masayuki Yamamoto, University of Tsukuba) was ligated into the EcoRV site of pcDNA3.1 (Invitrogen, Carlsbad, CA) to construct hGATA1 pcDNA3.1. GATA1 DN pcDNA3.1 was generated by using 1.3 kb of the PstI-EcoRI fragment from hGATA1 pcDNA3.1. GATA1 E2G pcDNA3.1 containing a missense mutation at codon 2 A4G derived from an AMKL patient, GATA1 ID pcDNA3.1, carrying an internal deletion (codons 77 to 119) derived from a TMD patient, 7 GATA1 DNF, DCF, DF, FC and DC pcDNA3.1 were generated by using PCR.
For CBFb pcDNA3.1, the sequence encoding full length of CBFb was amplified by PCR and inserted into the BamHI-XhoI site of pcDNA3.1. Similarly, to construct pcDNA4/HisMax AML1b, PCR was performed and the product was inserted into the KpnI-XhoI site of the pcDNA4/HisMax vector (Invitrogen).
To construct the PICA GPIba À253 reporter plasmid derived form the platelet GPIba promoter, we referred to the studies of Hashimoto and Ware. 17 The GPIba promoter region, containing 253 nucleotides 5 0 to the transcription start site, the nontranslated exon I, the single intron, and the first six base pairs of exon II immediately preceding the initiating methionine codon, was amplified by PCR and subcloned into the Picagene luciferase basic vector (Toyo Ink., Tokyo, Japan). The derived construct PICA GPIba À253 GATA mut was created using PCR, and then the blunt ended PCR products were self-ligated. Primers used were as follows: GPIb G1 mut S (5 0 -AGGCGAGCAGGGCTTG TGTCCAGG-3 0 , the underline shows mutated sequence) and GPIb G1 mut AS (5 0 -CACTCCACGGCTTTCCCCCAG-3 0 ).
Cell culture
COS-7, a green monkey renal epithelial cell line (Japanese Center Resources Bank, Tokyo, Japan) and QT6, a quail fibroblast cell line, were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS) at 371C in 5% CO 2 . The human megakaryoblastic cell lines CMK11-5 were established from a DS-AMKL patient. 18 CMK11-5 was obtained from the Institute for Fermentation, Osaka, Japan. The line was maintained in RPMI1640 with 10% FBS.
ChIP assay
CMK11-5 cells were transiently transfected with combinations of DNAs as follows: pcDNA4 His-Max, pcDNA4/HisMax AML1b, or pcDNA4/HisMax AML1b and pcDNA3.1 CBFbeta. Electroporation was carried out using Nucleofector (Amaxa, Gaithersburg, MD, USA) according to the supplier's methods. The transfection reagent T and the program T-20 were used. Chromatin fixation and purification procedures were as described previously. 19 Immunoprecipitations were carried out as described previously. 19 For the ChIP assay, an anti-Xpress antibody (Invitrogen) or an anti-GATA1 antibody (M20) (Santa Cruz Biotechnology, CA, USA) was used. The PCR products were electrophoresed using a Bioanalyzer 2100 and the DNA 1000 LabChip kit (Agilent Technologies, Palo Alto, CA, USA). Immunoprecipitation COS-7 cells were transfected using DMRIE-C reagent (Invitrogen). After 48 h, they were lysed in 1 ml of extraction buffer/ dish. 12 Cell lysates were centrifuged at 12 000 r.p.m. at 41C for 10 min. Immunoprecipitation was performed with 40 ml of M2 agarose (Sigma, St Louis, MO, USA) at 41C for 2 h followed by five washes with extraction buffer. These samples were then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting.
Immunoblotting
Cell extracts or immunoprecipitated samples were separated on SDS-PAGE and transferred to Hybond-P membranes (Amersham Biosciences, Tokyo, Japan). Immunodetections were carried out with anti-GATA1 (M20: Santa Cruz, Tokyo, Japan) anti-FLAG (M2: Sigma) antibodies and secondary antibodies conjugated with horseradish peroxidase. Detection of peroxidase activity was carried out with ECL Western blotting detection reagents (Amersham Biosciences, Tokyo, Japan).
Reporter gene assays
QT6 cells were seeded at a density of 4 Â 10 4 cells/well (12-well plate). Following overnight culture, the cells were transfected using lipofectamine reagent (Invitrogen) with a total of 0.8 mg DNA per well: 0.3 mg of luciferase reporter, 0.15 mg of each expression vector, and 50 ng of pENL b-galactosidase expression vector as an internal control. The cells were harvested 24 h after transfection, and cell extracts were assayed using the Picagene luciferase assay system (Toyo Ink., Tokyo, Japan). The results were standardized using a b-gal chemiluminescent reportergene assay system (Tropix Inc., Foster City, CA, USA).
Results
Transcriptional activity of the patient-specific GATA1 mutants
In most cases of TMD and DS-AMKL, the mutation in the GATA1 gene leads to expression of GATA1s (GATA1 DN) lacking the N-terminal activation domain (codons 1-83). [2] [3] [4] [5] [6] [7] We previously found two novel mutations in the N-terminal activation domain that resulted in the expression of a defective GATA1 protein, other than the N-terminal truncation. 7 The mutation found in a TMD patient led to an internal deletion of 43 amino acids (codons 77-119) in the activation domain of GATA1 (GATA1 ID) (Figure 1a) . In a DS-AMKL case, a missense mutation at codon 2 resulting in an amino-acid substitution (glutamic acid to glycine: GATA1 E2G) was detected. However, the effects of these mutations on the function of the resulting proteins remained unknown.
To investigate the function of these GATA1 mutants having a defective N-terminal activation domain, we first analyzed the transcriptional activity at the erythroid/megakaryocytic fNF-E2 promoter with functional GATA1-binding sites. 20 We transfected the reporter with the expression vectors for various GATA1 mutants into QT6 quail fibroblasts. 21 As expected, co-transfection with a GATA1 DN expression plasmid transactivated the reporter gene driven by the fNF-E2 promoter at a Physical association of GATA1 and RUNX1 G Xu et al reduced level (Figure 1b) . However, GATA1 E2G had an almost comparable level of transcriptional activity to that of wild-type GATA1. Surprisingly, GATA1 ID showed a higher level of reporter activity than did the wild-type GATA1. These results indicate that there is no direct correlation between the transcriptional activities at the GATA1 site and the oncogenic potential of these GATA1 mutants.
Physical association of the patient-specific GATA1 mutants with RUNX1
The function of GATA1 depends on its ability to bind both DNA and protein partners. Disruption of either of these functions causes severe hematopoietic dysfunction and results in blood disorders such as thrombocytopenia and anemia. The RUNX1 gene, located at the 'critical DS region' on chromosome 21, is a key regulator of megakaryopoiesis and is commonly mutated in leukemia. It was recently suggested that loss of the N-terminal portion of GATA1 might interfere with physiological interactions with RUNX1. To gain further insight into the mechanism of leukemogenesis in DS, we therefore examined the physical association of the GATA1 mutants and RUNX1 using a co-immunoprecipitation assay. As shown in Figure 2 , GATA1 DN, GATA1 ID and GATA1 E2G, as well as wild-type GATA1 expressed in COS-7 cells, were specifically co-immunoprecipitated with FLAG-tagged RUNX1 (AML1b). These results suggest that all of the patient-specific GATA1 mutants with a defective N-terminal portion can associate with RUNX1.
To determine domains critical in the physical interaction between GATA1 and RUNX1, we next expressed various GATA1 mutants (Figure 3a) and FLAG-tagged RUNX1 in COS-7 cells. Immunohistochemical staining showed that RUNX1 and each mutant GATA1 protein accumulated normally in the nuclei of the transfected cells. Although a small amount of GATA1 DF was detected in the cytoplasm, the protein accumulated in the nucleus was more abundant (Figure 3b) . Cellular extracts were immunoprecipitated using an anti-FLAG antibody (M2), and immunoprecipitates were immunoblotted with M2 (Figure 3c , upper) or the anti-GATA1 antibody (M20), which recognizes the C-terminus of GATA1 (Figure 3c, middle) . The deletion of either N-finger (GATA1 DNF) or C-finger (GATA1 DCF) regions resulted in a significant reduction of precipitation compared to wild-type GATA1, whereas control Western blots demonstrated the presence of comparable amounts of GATA1 DNF and GATA1 DCF in the lysates used for the immunoprecipitation assays (Figure 3c, bottom) . Furthermore, deletion of both zincfinger domains (GATA1 DF) completely abolished the binding of GATA1 to RUNX1. The GATA1 mutant containing only both finger domains and the C-terminal region (GATA1 FC) bound efficiently to RUNX1. These results indicate that the zinc-finger domain of GATA1 is essential for physical association with RUNX1.
RUNX1 binds to the megakaryocytic GPIba promoter in vivo
We next tested whether the defects in the N-terminal activation domain of GATA1 would affect the transcriptional activities of a megakaryocytic promoter with a consensus DNA-binding site Figure 1 The patient-specific GATA1 mutants having a defective N-terminal activation domain. (a) The structures of the patient-specific GATA1 mutants. The N-and C-terminal fingers are indicated by the black and gray boxes, respectively. GATA1 E2G has an amino-acid substitution (glutamic acid to glycine) owing to a missense mutation at codon 2. GATA1 ID has an internal deletion of 43 amino acids (codons 77-119) in the activation domain of GATA1. GATA1 DN (GATA1s) lacks the N-terminal activation domain (codons 1-83). (b) Regulation of the fNF-E2 promoter of p45 NF-E2 by GATA1 mutants. Representative data from one out of three independent experiments is shown. The results are the luciferase activity relative to that of mock (mean7s.d. of quadruplicate samples) . Each activity was standardized by reference to the b-galactosidase activity from the co-transfected expression plasmid, which was driven by the elongation factor 1 promoter. Figure 2 Physical interaction of the patient-specific GATA1 mutants with RUNX1. COS-7 cells were co-transfected with FLAG-tagged RUNX1 (AML1b), FLAG-tagged BAP, GATA1, GATA1 E2G, GATA1 ID, and GATA1 DN expression plasmids, as indicated. Cell lysates were immunoprecipitated using an anti-FLAG anitibody (M2). These samples were immunoblotted with the indicated antibodies, M2 (upper panel) or anti-GATA1 antibody (M20) (middle panel). The lower panel shows immunoblot analysis of the cell lysate using the M20 antibody.
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G Xu et al for RUNX1. In designing this experiment, we chose the megakaryocytic promoter of the GPIba gene because of its relatively simple structure. The GPIba promoter contains a single putative RUNX1 site, which was identified by the TFSEARCH program, and one functional GATA1-binding site (Figure 4a) . 17, 22 First, to ask whether RUNX1 actually binds to the GPIba promoter in vivo, we performed a ChIP assay. Because it is technically not feasible to use an anti-RUNX1 antibody for this assay, we transiently transfected Xpress-tagged RUNX1 with (Figure 4b  lanes 9-12) , or without (Figure 4b lanes 5-8) the CBFb expression vector into CMK cells derived from DS-AMKL, and ChIP assays were performed using anti-Xpress antibody. The results demonstrated that RUNX1 bound to the GPIba promoter specifically in vivo.
GATA1 mutants having a defective N-terminal activation domain are functional at the megakaryocytic promoter containing a RUNX1 site
To determine the functional consequences of the physical interaction between GATA1 and RUNX1, we conducted transactivation assays with luciferase reporter constructs driven by the megakaryocyte-specific GPIba promoter in QT6 cells. GATA1 alone and RUNX1 with CBFb each transactivated the GPIba reporter to a similar degree (Figure 5a ). As expected, marked synergy was observed between GATA1 and RUNX1 plus CBFb. GATA1 FC, which can interact with RUNX1, showed marginal synergy with RUNX1. In contrast, GATA1 DF, which lacks the ability to interact with RUNX1, did not show any synergy, ChIP analysis using an anti-GATA1 antibody (M20) and an anti-Xpress antibody. Gel images show PCR products corresponding to the GPIba promoter region, the HS2 of the b-globin gene. These were obtained using input (lanes 1, 5, and 9) and precipitated chromatin as templates (lanes 2, 3, 4, 6, 7, 8, 10, 11, and 12). Fragments containing the RUNX1 site and GATA1 site located in the GPIba promoter were precipitated with an anti-Xpress antibody or with M20. Normal mouse IgG was used as a control (lanes 2, 6, and 10). These results represent two independent experiments.
Physical association of GATA1 and RUNX1 G Xu et al although GATA1 DF retains the N-terminal transactivation domain. These results suggest that the physical interaction between GATA1 and RUNX1 is essential for the functional cooperation. We also examined the ability of the GATA1 DC lacking amino acids 319-413 to cooperate with RUNX1 in the activation of the GPIba promoter, because a recent report suggested that the C-terminus of GATA1 (amino acids 319-413) is critical for binding RUNX1. 12 Unexpectedly, GATA1 DC showed marked synergy with RUNX1, to a similar degree to that seen with wild-type GATA1. These results suggest that the C-terminus of GATA1 is dispensable for the physical interaction with RUNX1.
A previous report showed that the C-finger is essential to induce megakaryocytic differentiation of an early myeloid cell, and the N-finger is indispensable to pro-platelet formation. 23, 24 Although the deletion of either N-finger or C-finger region resulted in a significant reduction of precipitation compared to wild-type GATA1, these GATA1 mutants still bound to RUNX1. To further understand the functional cooperation of each finger with RUNX1, we next examined the transcriptional activity of GATA1 DNF and GATA1 DCF in the presence of RUNX1 and CBFb. GATA1 DNF showed significantly higher synergy with RUNX1 plus CBFb than did GATA1 (Figure 5c ). Surprisingly, no functional cooperation occurred between GATA1 DCF and RUNX1 plus CBFb. These results suggest that the C-finger of GATA1 plays an essential role in producing synergic effects of GATA1 with RUNX1.
The C-finger of GATA1 is essential for GATA1 function, as it is responsible for the recognition of the GATA consensus sequence and consequent binding to DNA. 25 To investigate the role of DNA-binding ability of the C-finger in producing the synergic effects of GATA1 and RUNX1, we generated luciferase reporter plasmids containing the GPIba promoter with a mutation in the functional GATA1 site, as described in a previous report. 17 As expected, introduction of the mutation in the GATA1-binding site resulted in markedly reduced transcriptional activity of GATA1 at the GPIba promoter, whereas RUNX1 could still activate the GPIba promoter (Figure 5b ). However, in the presence of RUNX1 and CBFb, GATA1, GATA1 FC and GATA1 DC synergistically activated the GPIba reporter with a mutation in the functional GATA1 site, although the reporter activities were reduced by about 50% compared to those of the intact GPIba promoter. These results suggest that the C-finger of GATA1 plays a very important role in modulating the transcriptional function of RUNX1 through non-DNA-binding mechanisms.
Among the patient-specific GATA1 mutants, GATA1 E2G had almost comparable levels of synergy with RUNX1 plus CBFb, whereas GATA1 DN had a reduced level of synergy. Interestingly, GATA1 ID showed a slightly higher level of reporter activities than did wild-type GATA1 in cooperation with RUNX1 plus CBFb (Figure 5a and b) . The levels of synergy seemed to be correlated with the transcriptional activities of Representative data of two independent experiments are shown. Each activity was standardized by reference to the b-galactosidase activity from the co-transfected expression plasmid, which was driven by the elongation factor 1 promoter. FL, full length GATA1; E2G, GATA1 E2G; ID, GATA1 ID; DN, GATA1 DN; FC, GATA FC; DF, GATA1 DF; DC, GATA1 DC. (b) A GPIba reporter mutant in which the functional GATA site was mutated was transiently co-transfected with various GATA1 mutants, with (lanes 4, 6, 8, 10, 12, 14, and 16) or without (lanes 3, 5, 7, 9, 12, and 15) RUNX1 plus CBFb expression plasmids. (c) The wild-type GPIba reporter was transiently co-transfected with various GATA1 constructs containing mutations in the zinc-finger domains, with or without RUNX1 plus CBFb expression plasmids in QT6 cells. Note that no functional cooperation occurred with GATA1 DCF and RUNX1 plus CBFb. DNF, GATA1 DNF DCF, GATA1 DCF.
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G Xu et al each GATA1 mutant. These results showed that all of the patient-specific GATA1 mutants retained their synergy with RUNX1 at the megakaryocytic promoter with GATA and RUNX1 sites, although the levels of transcriptional activities varied among them. Thus, our data indicate that perturbed transcriptional activities of the GATA1 mutants and RUNX1 complex may not be essential for development of leukemia in DS.
Discussion
GATA1 and RUNX1 are essential transcriptional regulators of normal megakaryocytic differentiation. Analysis of their cooperation in megakaryocytic differentiation may provide valuable information for understanding normal hematopoietic cell development and leukemogenesis. In this study, we found that patient-specific GATA1 mutant proteins having a defective N-terminal activation domain, corresponding to mutations associated with TMD and DS-AMKL, retained their ability to associate with RUNX1 and to form a complex with RUNX1 and CBFb to act synergistically on the megakaryocytic GPIba promoter. We mapped the GATA1 interaction domain that binds to RUNX1 to the zinc-finger domains and showed that the N-terminal activation domain is dispensable for the association with RUNX1. Members of the GATA and RUNX families of genes appear to have conserved their function in hematopoiesis from Drosophila to mammals. Waltzer et al. 15 demonstrated that the GATA factor Serpent (Srp) and the RUNX factor Lozenge (Lz) bind directly to each other through the conserved GATA zinc-finger and the RUNT domain, respectively. Although zinc-finger domains of GATA factors are well conserved from Drosophila to mammals, the srp gene is alternatively spliced to give rise to different isoforms containing either one (SrpC) or two (SrpNC) zincfingers. 26 SrpC contains only C-finger domain. They showed that deletion of the zinc-finger of SrpC resulted in complete loss of the interaction between Srp and Lz. 15 In contrast to SrpC, mammalian GATA factors have two zinc-fingers. We showed that loss of both fingers was necessary to completely abolish its physical interaction with RUNX1, suggesting that each finger may interact with RUNX1.
Deletion of the N-finger of GATA1 led to significantly higher synergy with RUNX1 plus CBFb than that seen for wild-type GATA1 in QT6 cells. The N-finger domain of GATA1 has been shown to stabilize the binding of the C-finger to palindromic GATA sites, although the N-finger itself is not capable of binding to the consensus GATA sequence. 27 The other important role of the N-finger domain is to recruit co-regulatory proteins such as FOG-1. 28 Because expression of FOG-1 is restricted to hematopoietic cells, other as-yet unknown co-factors might bind to the N-finger domain of GATA1 in QT6 cells and repress its function. Interestingly, deletion of the C-finger of GATA1 resulted in complete loss of synergy with RUNX1 at the GPIba reporter, whereas it retained the physical interaction with RUNX1. The C-finger of GATA1 functions as a protein-binding as well as a DNA-binding domain. Many protein partners have been shown to bind to the C-finger of GATA1. These include GATA1 itself, Kruppel-like factors (Sp1 and EKLF), and p300/ CBP. 28 CBP/P300 is particularly interesting, because it can serve as a bridging molecule between components of the transcriptional machinery and the enhanceosome complex. 29 Our data suggest that recruitment of co-activators or transcription factors through the C-finger of GATA1 may be necessary for synergy with RUNX1. Alternatively, it is still possible that the DNAbinding ability of GATA1 may play an essential role in the synergy with RUNX1, because wild-type GATA1 still activated the GPIba reporter having a mutation in the functional GATA1 site, although to a lesser level. It is still possible that GATA1 bound to the other GATA1 sites in the reporter. Actually, we found two putative GATA1 sites other than the mutated GATA1 site in the GPIba reporter. Interestingly, many megakaryocytic promoters and enhancers have both RUNX1-binding sites and GATA1-binding sites. 12, [30] [31] [32] [33] It will be intriguing to better understand the mechanisms of synergy between GATA1 and RUNX1, and experiments to further explore this interaction are now underway.
In summary, we have demonstrated that all of the patientspecific GATA1 mutants interacted efficiently with RUNX1 through their zinc-finger domains. They also retained their synergy with RUNX1 at the megakaryocytic GP1ba promoter containing GATA1-and RUNX1-binding sites. Thus, our data show that physical interaction and synergy between GATA1 and RUNX1 are retained in DS-AMKL, although it is still possible that an increased level of RUNX1 plays a role in the development of leukemia in DS.
